Publications by authors named "Bernhard Kogler"
Article Synopsis
- The study investigates adherence to PCSK9 inhibitor (PCSK9i) treatment for cardiovascular secondary prevention in Austria, where treatment costs are fully covered.
- Data from 7,302 patients showed an average adherence rate (proportion of days covered) of 81.8%, with 73.8% of patients deemed adequately adherent.
- The findings reveal that while 27.4% discontinued treatment (mostly within the first year), almost half of those who stopped later resumed, indicating that high adherence is achievable with no-cost access.
Reimbursement decisions on new medicines require an assessment of their value. In Austria, when applying for reimbursement of new medicines, pharmaceutical companies are also obliged to submit forecasts of future sales. We systematically examined the accuracy of these pharmaceutical sales forecasts and hence the usefulness of these forecasts for reimbursement evaluations.
View Article and Find Full Text PDFPurpose: Guideline-recommended therapy has been proven beneficial in heart failure (HF), but general implementation remains poor. The aim of this study was to evaluate the adherence to drug therapy, quality of primary non-drug medical care (NDMC) and its impact on HF outcome.
Methods: From 13 Austrian health insurance funds, we identified 36 829 patients (77.